Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Front Neurol ; 12: 671738, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34393971

RESUMO

Men with erectile dysfunction (ED) are considered to be at risk from stroke events. Conversely, post-stroke patients are also at high risk of ED, whereas a quantitative result from all the relevant studies has not been previously addressed. Therefore, we have performed a comprehensive review and meta-analysis on this issue. This study was registered on PROSPERO (ID No. CRD42021226618). Twenty studies with a total of 3,382 stroke events were included, of which six studies were included for quantitative analysis, and the remaining 14 studies were calculated for the ratio of ED. Synthetic results from four eligible studies providing the ED cases showed that stroke patients were associated with a significantly higher risk of ED than the general population [pooled relative risk (RR) = 3.32, 95% confidence interval (CI): 1.25-8.82, P = 0.016]. Men with stroke were also found to be associated with a significant decline in International Index of Erectile Function -5 (IIEF-5) score as compared with the healthy controls [three studies, standard mean differences (SMD) = -1.8, 95% CI: -2.94 to -0.67, P = 0.002]. The prevalence of ED in post-stroke patients among 14 studies ranged from 32.1 to 77.8%, which was dramatically higher than that of the general population. The result of the GRADE-pro revealed that the quality of the evidence in this study was moderate. The present study has confirmed the high prevalence of ED in men with stroke. ED in stroke patients is a result of both neurological and psychological factors. Rehabilitative interventions rather than phosphodiesterase-5 (PDE-5) inhibitors are recommended to improve the erectile function for those survivors with ED.

2.
Eur J Surg Oncol ; 45(12): 2379-2385, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31445769

RESUMO

INTRODUCTION: Synovial sarcoma (SS) is a tumor of unknown origin and is extremely rare in the central nervous system. Most studies on intracranial SS included only one or two cases. To better understand the disease, we review a series of primary intracranial SS. METHOD AND MATERIALS: 16 primary intracranial SS in Tiantan Hospital during 2008-2017 were included. The clinical characteristics, including radiological and histological examination, operative records, and prognoses were reviewed. RESULT: The case series included nine male and seven female patients with an average age of 23.8 years. Radiological results showed that the supratentorial region (81.25%) was the most common site of the brain involved. All patients were misdiagnosed as non-SS tumors. Gross total resection (GTR) was achieved in 12 cases (75.0%), and subtotal resection (STR) was achieved in 4 cases. All cases showed the characteristic SYT-SSX fusion gene, as detected by RT-PCR. The mean progression-free survival time (PFS) was 10.0 months and the mean overall survival time (OS) was 15.5 months. Multivariate analysis revealed that GTR and postoperative adjuvant radiotherapy were independent factors for PFS (HR = 6.143, 95% CI = 1.491-25.312; P = 0.012, HR = 6.143, 95% CI = 1.491-25.312; P = 0.012 respectively) and OS (HR = 9.000, 95% CI = 1.627-49.773; P = 0.012, HR = 0.017, 95% CI = 0.001-0.213; P = 0.002 respectively). CONCLUSION: Intracranial SS were more frequently observed in the supratentorial region and in young patients without sex predilection. We recommend adjuvant radiation regardless of the extent of resection. More patients and longer follow-up periods were needed to further elucidate the biological features of intracranial SS.


Assuntos
Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/cirurgia , Sarcoma Sinovial/radioterapia , Sarcoma Sinovial/cirurgia , Adolescente , Adulto , Idoso , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/patologia , Pré-Escolar , Diagnóstico por Imagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Intervalo Livre de Progressão , Radioterapia Adjuvante , Estudos Retrospectivos , Sarcoma Sinovial/mortalidade , Sarcoma Sinovial/patologia , Taxa de Sobrevida
3.
Int J Clin Exp Pathol ; 10(7): 7661-7669, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-31966611

RESUMO

The objective of this study was to explore the expression and the clinical and prognostic significance of prokineticin 1 (PROK1) in human gliomas. The expression of PROK1 in 60 patients with glioma and in eight control cases (patients with traumatic brain injury) by immunohistochemistry (IHC). The associations between the differences in expression and pathology grades were analyzed statistically. The positive rates of PROK1 expression in normal brain and glioma tissue were 25.0% (2/8) and 93.3% (56/60), respectively. PROK1 expression in glioma tissue was higher than that in normal tissue (P<0.05). The positive rates of PROK1 expression in low-grade gliomas (LGGs, grades I and II) and high-grade gliomas (HGGs, grades III and IV) were 66.7% (8/12) and 100% (48/48), respectively, the positive rates in HGG were higher than those in LGG (P<0.01). PROK1 is an angiogenic growth factor that is related with metastatic ability of tumor, we also correlated PROK1 expression with NFAT expression. Expression of PROK1correlated significantly with expression of NFAT (r=0.524, P<0.01), but not with patient sex and age. Glioma patients with higher expressing PROK1 had a significantly shorter progression-free survival time, increasing levels of PROK1 expression significantly correlated with reduced survival times when all patients with glioma were considered (P<0.01). These results suggested that PROK1 positivity and protein expression levels are of significant clinical and prognostic value in human gliomas, which significantly correlates with the survival in gliomas, PROK1 may regulate the progression of glioma via the NFAT pathway.

4.
J Transl Med ; 11: 172, 2013 Jul 17.
Artigo em Inglês | MEDLINE | ID: mdl-23866847

RESUMO

BACKGROUND: MicroRNAs have recently emerged as key regulators of cancers, miR-329 located on 14q32.31 is one of down-regulated miRNAs in glioma, but the function and molecular mechanisms of miR-329 in determining the malignant phenotype of human glioma are elusive. This study therefore was conducted to investigate the role of miR-329 in biological behaviors of human glioma LN18 and T98G cell lines and its molecular mechanisms. METHODS: Nine patients with GBM were analyzed for the expression of miR-329 by quantitative RT-PCR. MiR-329 overexpression was established by transfecting miR-329 precursor into LN18 and T98G cells, and its effects on cell proliferation were studied using MTT assay, anchorage-independent growth ability assay, colony formation assays, Bromodeoxyuridine labeling and immunofluorescence.The effects of miR-329 on cell cycle were studied by flow cytometry. The target of miR-329 was determined by luciferase assays. The regulation of miR-329 on Akt pathway was determined by western blot. RESULTS: The E2F1 was identified as the target of miR-329. Overexpression of miR-329 blocked G1/S transition in LN18 and T98G cell lines, dramatically suppressed cell proliferation and the ability of colony formation. MiR-329 significantly decreased the phosphorylation levels of intracellular kinases Akt and expression of cyclin D1, but the expression of p21 was upregulated, cell growth was suppressed by inhibiting E2F1-mediated Akt pathway. CONCLUSIONS: MiR-329 may inhibit cell proliferation in human glioma cells through regulating E2F1-mediated suppression of Akt pathway.


Assuntos
Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patologia , Fator de Transcrição E2F1/metabolismo , Glioma/genética , Glioma/patologia , MicroRNAs/metabolismo , Regiões 3' não Traduzidas/genética , Sequência de Bases , Linhagem Celular Tumoral , Proliferação de Células , Regulação para Baixo/genética , Regulação Neoplásica da Expressão Gênica , Humanos , MicroRNAs/genética , Dados de Sequência Molecular , Proteínas Proto-Oncogênicas c-akt/metabolismo , Transdução de Sinais/genética , Regulação para Cima/genética
5.
Zhonghua Wai Ke Za Zhi ; 49(8): 699-702, 2011 Aug 01.
Artigo em Chinês | MEDLINE | ID: mdl-22168932

RESUMO

OBJECTIVE: To review the preliminary clinical experience with high-field-strength intra-operative magnetic resonance imaging (iMRI) in the endoscopic chordoma operation with transsphenoidal or transoral approach. METHODS: From January 2009 to December 2010, 23 patients [range, 29 - 64 years, mean age (42 ± 3) years] of chordoma were operated with endoscopic transsphenoidal or transoral approach and examined intraoperatively with a movable 1.5 T iMRI magnet. Tumor size range was 2.0 - 5.7 cm, mean (3.5 ± 0.8) cm. A navigation system based on iMRI was used in 20 cases. RESULTS: iMRI scan were performed in each operation from 1 time to 5 times. Neuronavigation system were used in 20 operations and the data renewed in 12 cases by the information from iMRI. In 15 of 23 patients, iMRI had revealed residual lesions and resulted in 12 cases further treatment, eventually, 9 tumors were totally removed and 3 tumors were further removed. The ratio of total removal tumor was enhanced to 73.9% (17/23) from 34.8% (8/23). Among 15 cases of partial chordoma removal detected by scanning in operation, 9 were huge chordoma. The residual of huge chordoma detected by scanning in operation was 9/11, and other chordoma contributed to 6/12. There were no iMRI related safety issue or accident recorded in this study. CONCLUSIONS: High-field-strength iMRI provide high-quality images of tumor resection that allows intraoperative modification of the surgical strategy. Combined with the navigation system, iMRI is helpful to maximize the resection of the chordoma and benefit for the safety of endoscopic operation.


Assuntos
Cordoma/cirurgia , Imageamento por Ressonância Magnética/métodos , Neuronavegação/métodos , Neoplasias Hipofisárias/cirurgia , Adulto , Endoscopia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Seio Esfenoidal/cirurgia
6.
Chin Med J (Engl) ; 120(9): 749-54, 2007 May 05.
Artigo em Inglês | MEDLINE | ID: mdl-17531112

RESUMO

BACKGROUND: In most colorectal carcinomas, the level of phospholipase C (PLC)-gamma 1 expression is greatly elevated. Increased expression of PLC-gamma 1 may play an important role in colon carcinogenesis, but the mechanism is not well known. The aim of this study was to evaluate the role of PLC-gamma 1 in colon carcinogenesis by using recombinant lentivirus that stably suppressed the PLC-gamma 1 expression in human colorectal carcinoma LoVo cells. METHODS: Recombinant lentivirus producing PLC-gamma 1 siRNA were prepared. After LoVo cells were transduced by each lentivirus, stably transduced cells were selected by Blasticidin. The protein and mRNA expression of PLC-gamma 1 were examined by Western-blot and reverse transcription-polymerase chain reaction (RT-PCR) analysis, and the effects of the lentivirus on the cell adhesion, migration and apoptosis were analyzed. RESULTS: Stable LoVo cell line deficient in PLC-gamma 1, was established. Notably, PLC-gamma 1 was silenced without affecting the levels of other subtypes of PLC so that the role of PLC-gamma 1 in colon carcinogenesis could be examined. Silencing of endogenous PLC-gamma 1 resulted in efficient inhibition of the adhesion and migration of LoVo cells in vitro and a great increase of 5-fluorouracil induced apoptosis (30%-40%) of LoVo cells. CONCLUSIONS: PLC-gamma 1 may play an important role in metastasis and anti-apoptosis in human colorectal carcinomas.


Assuntos
Neoplasias Colorretais/terapia , Lentivirus/genética , Fosfolipase C gama/antagonistas & inibidores , RNA Interferente Pequeno/uso terapêutico , Apoptose/efeitos dos fármacos , Adesão Celular , Linhagem Celular Tumoral , Neoplasias Colorretais/patologia , Fluoruracila/farmacologia , Humanos , Laminina/antagonistas & inibidores , Laminina/genética , Fosfolipase C gama/genética , Fosfolipase C gama/fisiologia
7.
Conf Proc IEEE Eng Med Biol Soc ; 2005: 5215-8, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-17281424

RESUMO

In this experiment, the bone marrow stroma cells (BMSCs) were harvested and then cultured in "neural stem cells (NSCs) medium" which was modulated by our lab with P. R. of China patent number as ZL 02134314.4 in vitro. The proliferation of NSCs was confirmed by formation of cell's clones and scan electron microscopy test. The identifications of NSCs, neurons-like cells and glial-like cells were immunocytochemically performed by detecting Nestin, neuron-specific enolase (NSE), and glial fibrillary acidic protein (GFAP). Neurons-like cells were further identified by detecting excitability amino acid, inhibited amino acid, or monoamine biological activity materials with high pressure liquid chromatograph (HPLC), and also by examining the electrophysiological properties with patch clamp, in order to verify their neuron-like functions. It was implied that the differentiated BMSCs-NSCs-derived neuron-like cells were characterized by both the neuron-like bio-chemical function and some corresponding electrophysiological properties.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA